文献速递糖尿病性腺与生殖内分泌

使用激素治疗的跨性别个体糖尿病发病风险未增加

Incident Diabetes Risk Is Not Increased in Transgender Individuals Using Hormone Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该回顾性队列研究将1972至2018年阿姆斯特丹性别烦躁队列中使用激素治疗的跨性别个体与全国健康数据登记库链接,以首次发放降糖药物推断糖尿病发生,计算标准化发病比(SIR)。与出生指定性别的一般人群相比,跨性别女性(N=2585,90例;SIR 0.94;95%CI 0.76-1.14)和跨性别男性(N=1514,32例;SIR 1.40;95%CI 0.96-1.92)的2型糖尿病发病率均无差异。

要点

  • 跨性别女性使用激素治疗后2型糖尿病发病率与出生指定性别一般人群相比无差异(SIR 0.94;95%CI 0.76-1.14)。
  • 跨性别男性使用激素治疗后2型糖尿病发病率与出生指定性别一般人群相比无差异(SIR 1.40;95%CI 0.96-1.92)。
  • 尽管女性化激素治疗可增加胰岛素抵抗、男性化激素治疗可降低胰岛素抵抗,但激素治疗后糖尿病发病率与一般人群无差异。

核心结论

  • 尽管有研究报道女性化激素治疗增加胰岛素抵抗、男性化激素治疗降低胰岛素抵抗,跨性别个体开始激素治疗后糖尿病发病率与一般人群相比无差异。

研究设计与样本

  • 回顾性数据来自阿姆斯特丹性别烦躁队列,纳入1972年至2018年间使用激素治疗的跨性别个体,并与全国健康数据登记库链接。
  • 因无中央糖尿病登记库,糖尿病发生根据首次发放降糖药物推断。
  • 计算跨性别女性和跨性别男性与一般人群同出生性别的标准化发病比(SIR)。

主要发现

  • 与出生指定性别一般人群相比,跨性别女性2型糖尿病发病率无差异(N=2585,90例;SIR 0.94;95%CI 0.76-1.14)。
  • 与出生指定性别一般人群相比,跨性别男性2型糖尿病发病率无差异(N=1514,32例;SIR 1.40;95%CI 0.96-1.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In trans women receiving hormone therapy, body fat and insulin resistance increases, with opposite effects in trans men. These metabolic alterations may affect the risk of developing type 2 diabetes in trans women and trans men. CONTEXT: We aimed to compare the incidence of type 2 diabetes of adult trans women and trans men during hormone therapy with rates from their birth-assigned sex in the general population. METHODS: Retrospective data from the Amsterdam Cohort of Gender Dysphoria with transgender individuals on hormone therapy between 1972 and 2018 were linked to a nationwide health data registry. Because no central registry of diabetes is available, the occurrence of diabetes was inferred from the first dispense of a glucose-lowering agent. Standardized incidence ratios (SIR) were computed for trans women and trans men in comparison with the same birth sex from the general population. RESULTS: Compared with their birth-assigned sex in the general population, no difference in the incidence of type 2 diabetes mellitus was observed in trans women (N = 2585, 90 cases; SIR 0.94; 95% CI, 0.76-1.14) or trans men (N = 1514, 32 cases; SIR 1.40; 95% CI, 0.96-1.92). CONCLUSION: Despite studies reporting an increase in insulin resistance in feminizing hormone therapy and a decrease in insulin resistance in masculinizing hormone therapy, the incidence of diabetes in transgender individuals after initiation of hormone therapy was not different compared with the general population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. van Velzen D, Wiepjes C, Nota N, et al. Incident Diabetes Risk Is Not Increased in Transgender Individuals Using Hormone Therapy. J Clin Endocrinol Metab. 2022. PMID: 34971391. doi:10.1210/clinem/dgab934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。